
Colorectal Cancer Treatment Options in China: Targeted Therapy, Immunotherapy and Innovative Drugs
Colorectal cancer (CRC) is one of the most common malignant tumors worldwide and remains a…

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide and remains a…

In February 2026, several new cancer drugs approved by global regulatory authorities marked significant progress…

According to the National Medical Products Administration (NMPA), three innovative drugs were approved for marketing…

As the global pharmaceutical supply chain evolves, China is emerging as a key player in…

In today’s increasingly competitive global pharmaceutical landscape, choosing a reputable pharmaceutical wholesaler has become a…

In May 2023, China’s National Medical Products Administration (NMPA) approved the first domestically developed generic…

In recent years, immune checkpoint inhibitors have revolutionized the field of anti-tumor treatment, among which…

In the treatment of leukemia, not all patients respond equally to standard therapies. Drug resistance…

Adebrelimab approval in China marks a significant milestone in the country’s oncology landscape. In 2023,…

Multiple myeloma is a chronic and often relapsing hematologic malignancy that requires long-term, repeated treatment.…